Abstract
Surgical intervention in the patients with metastatic renal cancer can occur in two settings: (1) to render a patient clinically free of all sites of primary disease and metastases, termed nephrectomy/metastasectomy, or (2) to resect the primary tumor in the face of unresectable metastatic disease prior to the initiation of systemic therapy, termed cytoreductive nephrectomy. Carefully selected patients with good performance status undergoing nephrectomy and subsequent metastasectomy may experience prolonged survival in the range of 30 months, which could be attributed to a combination of patient selection factors and the surgical resections. Randomized clinical trials from the United States and Europe have demonstrated a small but significant survival benefit to cytoreductive nephrectomy and cytokine therapy versus cytokine therapy alone which is measured in the range of 3–6 months and associated with overall survival of approximately 12 months. The precise mechanism by which cytoreductive nephrectomy improves survival is not known but may relate to reduction in the large primary immunosuppressive burden. Patient selection factors including performance status and serum factors (Hgb, corrected Ca++, LDH) stratify metastatic patients into risk groups, which are strongly associated with survival time in both medically and surgically treated patients with metastatic renal cancer. The development of multi-kinase and mTOR inhibitors has markedly improved survival in treatment naïve and previously treated patients with metastatic renal cancer , and these agents are currently under active clinical investigation in the neo-adjuvant and adjuvant setting.
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. Ca Cancer J Clin 59:225–249
Motzer RJ, Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163:408–417
Rini B, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373:1119–1132
Kroog GS, Motzer RJ (2008) Systemic therapy for metastatic renal cell carcinoma. Urol Clin N Am 35:687–701
Russo P, O’Brien MF (2008) Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy. Urol Clin North Am 35:679–686
Barney JD, Churchill EJ (1939) Adenocarcinoma of the kidney with metastasis to the lung: cured by nephrectomy and lobectomy. J Urol 42:269–276
Giuliani L, Giberti C, Martorana G et al (1990) Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 143:468–473
Pogrebniak HW, Haas G, Linehan WM et al (1992) Renal cell carcinoma: resection of solitary and multiple metastases. Ann Thorac Surg 54:33–38
Kavolius JP, Mastorakos DP, Pavolvich C, Russo P, Burt ME, Brady MS (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol 16:2261
Russo P, Snyder M, Vickers A, Kondagunta V, Motzer R (2007) Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. TSW Urol 2:42–52
Walther MM, Yang JC, Pass HI, Linehan WM, Rosenberg SA (1997) Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 158:1675
Kutikov A, Uzzo RG, Caraway A, Reese CT, Egleston BL, Chen DY, Viterbo R, Greenberg RE, Wong YN, Raman JD, Boorjian SA (2009) Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int [Epub ahead of print]
Bex A, Haanen J, Vyth-Dreese FA, Hornblas S, de Gast GC (2008) Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal cell-clear carcinoma of intermediate prognosis. Urol Int 80:367–371
Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon α 2-b compared with interferon alfa-2b alone for metastatic renal cell carcinoma. N Engl J Med 345:1655–1659
Mickisch GHJ, von Poppel H, de Prijck L, Sylvester R et al (2001) Radical nephrectomy plus interferon–alfa based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomized trial. Lancet 358:966–970
Flanigan RC, Mickisch G, Sylvester R, Tangen C, von Poppel HV, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171:1071–1076
Russo P (2009) Contemporary cytoreductive nephrectomy in patients with mRCC. CML Kidney Cancer 1:33–41
Bromwich E, Hendry D, Aitchison M (2002) Cytoreductive nephrectomy: is it a realistic option in patients with renal cancer. BJU Int 89:523–525
Motzer RJ, Mazumdar M, Bacik J et al (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2859–2867
Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P (2006) Renal cell carcinoma recurrence after nephrectomy for localized disease. Predicting survival from time of recurrence. J Clin Oncol 24:3101–3131
Shuck B, LaRochelle JC, Wu J, Klatte T, Riggs SP, Kabbinavar F, Belledegrun AS, Pantuck AJ (2008) Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer 113:1324–1331
Halbert RJ, Figlin RA, Atkins MB et al (2006) Treatment of patients with metastatic renal cell cancer: a RAND appropriateness panel. Cancer 107:2375–2383
Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA, Novick AC, Campbell SC (2009) Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 181:518–523
Margulis V, Matin S, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG (2008) Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 180:94–98
Neill MG, Jewett MAS (2008) The once and future role of cytoreductive nephrectomy. Urol Oncol 26:346–352
Coppin C, Le L, Porzolt F, Wilt T (2008) Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev Issue 2, Art. No CD 006017
Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V (2002) Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear cell histology. J Clin Oncol 20:2376–2381
Raberts JC, Kaouk J, Fergany A et al (2004) Laparoscopic v open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology 64:930–934
Matin SF, Madsen LT, Wood CG (2006) Laparoscopic cytoreductive nephrectomy: the M.D. Anderson Cancer Center Experience. Urology 68:528–532
Bhojani N, Jeldres C, Patard JJ et al (2008) Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53:917–930
Conflicts of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Russo, P. Multi-modal treatment for metastatic renal cancer: the role of surgery. World J Urol 28, 295–301 (2010). https://doi.org/10.1007/s00345-010-0530-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-010-0530-x